These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33518465)

  • 21. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of measles-mumps-rubella (MMR) vaccination in the prevention of pediatric hospitalizations for targeted and untargeted infections: A retrospective cohort study.
    La Torre G; Saulle R; Unim B; Meggiolaro A; Barbato A; Mannocci A; Spadea A
    Hum Vaccin Immunother; 2017 Aug; 13(8):1879-1883. PubMed ID: 28604255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines.
    Habib MA; Povey M; Casabona G; Singh T; Abu-Elyazeed R
    Hum Vaccin Immunother; 2023 Dec; 19(1):2188852. PubMed ID: 36988468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.
    Böttiger M; Christenson B; Romanus V; Taranger J; Strandell A
    Br Med J (Clin Res Ed); 1987 Nov; 295(6608):1264-7. PubMed ID: 3120971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.
    Woudenberg T; van der Maas NAT; Knol MJ; de Melker H; van Binnendijk RS; Hahné SJM
    J Infect Dis; 2017 Apr; 215(8):1181-1187. PubMed ID: 28368471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T; Eda M; Hirano M; Goto W
    Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial.
    Vittrup DM; Laursen ACL; Malon M; Soerensen JK; Hjort J; Buus S; Svensson J; Stensballe LG
    Trials; 2020 Dec; 21(1):1015. PubMed ID: 33303011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial.
    Zimakoff AC; Jensen A; Vittrup DM; Herlufsen EH; Sørensen JK; Malon M; Svensson J; Stensballe LG
    BMJ; 2023 Jun; 381():e072724. PubMed ID: 37286215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm.
    Jama A; Ali M; Lindstrand A; Butler R; Kulane A
    Int J Environ Res Public Health; 2018 Nov; 15(11):. PubMed ID: 30388799
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.